Back to Search Start Over

Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.

Authors :
Hakami AR
Bakheit AH
Almehizia AA
Ghazwani MY
Source :
Future medicinal chemistry [Future Med Chem] 2022 Jan; Vol. 14 (2), pp. 61-79. Date of Electronic Publication: 2021 Nov 24.
Publication Year :
2022

Abstract

Background: Conserved domains within SARS-CoV-2 nonstructural proteins represent key targets for the design of novel inhibitors. Methods: The authors aimed to identify potential SARS-CoV-2 NSP5 inhibitors using the ZINC database along with structure-based virtual screening and molecular dynamics simulation. Results: Of 13,840 compounds, 353 with robust docking scores were initially chosen, of which ten hit compounds were selected as candidates for detailed analyses. Three compounds were selected as coronavirus NSP5 inhibitors after passing absorption, distribution, metabolism, excretion and toxicity study; root and mean square deviation; and radius of gyration calculations. Conclusion: ZINC000049899562, ZINC000169336666 and ZINC000095542577 are potential NSP5 protease inhibitors that warrant further experimental studies.

Details

Language :
English
ISSN :
1756-8927
Volume :
14
Issue :
2
Database :
MEDLINE
Journal :
Future medicinal chemistry
Publication Type :
Academic Journal
Accession number :
34814706
Full Text :
https://doi.org/10.4155/fmc-2020-0380